Investment Fact Sheet for DiaTech Oncology Ltd

Investment	DiaTech Oncology Ltd.
Nature of Investment	£1 Redeemable Preference shares (RPS) in a Special Purpose Company holding IP assets. Each redeemable preference shares comes with a priority preference share at no additional cost.
Minimum Investment	£40,000
Leveraging	Each RPS carries a warrant for four (4) additional RPS that are exercised at the time of a liquidity event, with such warrants funded by the proceeds of said liquidity event.
Valuation	Asset valued at £660m when fully funded.
Product	Microculture Kinetic Assay (MiCK), is a transformative patient-specific treatment-directing platform that specifies the most effective chemotherapy options (CHEMOINTEL) and immunotherapy options (IMMUNOINTEL) for any given patient. DiaTech rationalizes and "personalizes" the use of chemotherapy and immunotherapy in the fight against cancer, and improves the probability of selecting the best treatment, which will result in improved patient outcomes.
Developer	Perian Holdings, Inc. Nashville Tennessee, USA.
Development Plan	The Company will execute a series of tumour-specific trials that will provide unequivocal "proofs" that patient outcomes are improved as a consequence of cytotoxic drug treatment selection and/or immunotherapy based on DiaTech assay.
Exit	Liquidity event via disposition of the asset or company, IPO, or any other equivalent transaction.
Term	1-3 years from January 2021.
Total Funding	£70m. (£20m remaining)
Return	Return of initial investment from proceeds of Liquidity Event, with additional participation in upside through RPS warrants to 850% of initial investment.
ISIN and SEDOL	UNSECURED NON VTG RED PREF GBP0.000001 **Price £1** **ISIN GB00BYX3X606** **SEDOL BYX3X60** Priority shares to be applied for at nil cost together with RPSs above UNSECURED NON VTG PRTY PREF GBP0.000001 **ISIN GB00BYX3X713** **SEDOL BYX3X71**
Bank Account	Bank: Barclays Bank Bank Address: Leicester, Leicestershire. LE87 2BB Sort Code: 20-01-58 Account No. 83107736 Account Name: Diatech Oncology Ltd Receiving A/c IBAN: GB20 BUKB 20015883107736 Swift Code: BUKBGB22

Investment Fact Sheet for Vaccicure Ltd

Investment	Vaccicure Limited
Nature of Investment	£1 Redeemable Preference shares (RPS) in a Special Purpose Company holding IP assets. Each redeemable preference share comes with a priority preference share at no additional cost.
Minimum Investment	£40,000
Leveraging	Each RPS carries warrants for four (4) additional RPS that are exercised at the time of a liquidity event, with such warrants funded by the proceeds of said liquidity event.
Valuation	Asset valued at £767m when fully funded.
Product	A fusion peptide demonstrated to stimulate the immune systems of patients to neutralize the hormone gastrin, specifically G17 a known driver of major gastrointestinal cancers including pancreatic, gastric and colorectal.
Developer	Cancer Advances (a division of Cato Research), North Carolina, USA.
Development Plan	Cancer Advances polyclonal Antibody Stimulator (PAS) product has undergone 22 clinical studies in over 1,500 patients examining pharmacology, efficacy, safety, tolerability, dosage and scheduling in pancreatic, gastric and colorectal cancers. Primary efficacy studies identified a significant increase in median survival for patients with both pancreatic and gastric cancers when given PAS. A pivotal Phase 3 pancreatic cancer study has been submitted to the FDA. An additional Phase 3 study to support this is asked for by the FDA that will include a Phase 3 trial with ~500 patients using large scale manufactured PAS. The Company will utilise the Fast Track designation for PAS from the FDA for both pancreatic and gastric indications.
Exit	Liquidity event via disposition of the asset or company, IPO, or any other equivalent transaction.
Term	1 - 2 years from January 2021.
Total Funding	£45m. (£25m remaining)
Return	Return of initial investment from proceeds of Liquidity Event, with additional participation in upside through RPS warrants to 850% of initial investment.
ISIN and SEDOL	Vaccicure Ltd GBP0.000001 RED PREF **ISIN** **GB00BD5K1358** **SEDOL** **BD5K135** Priority shares to be applied for at nil cost together with RPSs above Vaccicure Ltd GBP0.000001 PREF PRIORITY **ISIN** GB00BD5K1572 **SEDOL** BD5K157
Bank Account	Barclays Bank Bank Address: Leicester, Leicestershire. LE87 2BB Sort Code: 20-01-58 Account No. 13516253 Account Name: Vaccicure Ltd Receiving IBAN: GB59BARC20000013516253 Swift Code: BARCGB22